BIO Asia International Conference

March 9-10, 2021・Grand Hyatt Tokyo, Japan
Accelerate your Pathway to Partnerships in Asia.

About the BIO Asia International Conference

The BIO Asia International Conference in Tokyo brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market and throughout the region.  Companies with more than 460 therapeutic assets from more than 25 countries pursued Partnering discussions at the 2019 Tokyo conference.

#BIOASIA19 At a Glance
1,270
+
BIO One-on-One Partnering Meetings
50
Presenting Companies
27
Participating Countries

Assets by Therapeutic Area

  Therapeutic Area
Neoplasm
Inflammatory disease
Immune disorder
Neurological disease
Gastrointestinal disease
Respiratory disease
Musculoskeletal disease
Psychiatric disorder
Hematological disease
Dermatological disease
Ocular disease
Cardiovascular disease
Infectious disease
Gynecology and obstetrics
Degeneration
Other
Assets
107
97
69
58
50
47
33
28
25
22
22
21
19
12
10
49
Increase Since Last Update
+6
+4
+3
+7
+3
+1
+1
0
+2
+4
+3
+1
0
+2
0
+5

*as of February 14, 2020

 

Participating Investors

Meet the venture capital and private equity investors focused on cross-border biotechnology development who are currently active in the partnering system and ready to meet.
Aceras Life Sciences | Asset Management Ventures | BioInnovation Capital | Chaperone Investment Eight Roads Ventures |  Japan First Republic Bank Hannol Ventures Harbin Pharma | JAFCO Mitsubishi UFJ Capital Mitsui Global Investment |  Momentum Biotech MSQ Ventures Otsuka Pharmacautical Co. Premir Partners Shinsei Capital Partners W Global Capital

EVT-ASIA20_Partnering